Table 3 Total treatment-emergent adverse events (intent-to-treat population, n = 119)
Adverse event | n (%) |
|---|---|
'Flu-like' symptoms | 170 (39.4) |
Headache | 84 (19.4) |
Injection-site reaction | 46 (10.6) |
Gastrointestinal abnormalities | 25 (5.8) |
Pain | 20 (4.6) |
Anxiety | 13 (3.0) |
Infections | 10 (2.3) |
Hypersensitivity reaction | 7 (1.6) |
Cytopenia | 7 (1.6) |
Hepatic disorders | 7 (1.6) |
Vertigo | 6 (1.4) |
Upper respiratory tract infection | 5 (1.1) |
Tachycardia | 4 (0.9) |
Dysmenorrhoea | 3 (0.7) |
Other | 25 (5.8) |
Total | 432 (100) |